Immuneering (IMRX)
(Real Time Quote from BATS)
$1.89 USD
+0.05 (2.72%)
Updated Apr 17, 2024 03:56 PM ET
After-Market: $1.86 -0.03 (-1.59%) 4:16 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Immuneering Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 2 | 2 | NA |
Cost Of Goods | 0 | 0 | 1 | 1 | NA |
Gross Profit | 0 | 0 | 1 | 1 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 58 | 52 | 35 | 18 | 0 |
Income After Depreciation & Amortization | -58 | -52 | -34 | -17 | 0 |
Non-Operating Income | 5 | 1 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -53 | -51 | -34 | -17 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -53 | -51 | -34 | -17 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -53 | -51 | -34 | -17 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -59 | -51 | -34 | -17 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | NA |
Income After Depreciation & Amortization | -58 | -52 | -34 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.42 | 26.39 | 13.61 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.88 | -1.91 | -2.46 | NA | NA |
Diluted Net EPS (GAAP) | -1.88 | -1.91 | -2.46 | NA | NA |
Fiscal Year end for Immuneering Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.30 | 13.93 | 13.50 | 14.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.30 | -13.93 | -13.50 | -14.68 |
Non-Operating Income | NA | 1.22 | 1.33 | 1.32 | 1.08 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -15.08 | -12.60 | -12.19 | -13.60 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -15.08 | -12.60 | -12.19 | -13.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -15.08 | -12.60 | -12.19 | -13.60 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.27 | 29.27 | 28.65 | 26.44 |
Diluted EPS Before Non-Recurring Items | NA | -0.52 | -0.43 | -0.43 | -0.51 |
Diluted Net EPS (GAAP) | NA | -0.51 | -0.43 | -0.43 | -0.51 |